We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca May Skip EUA Process and Seek Full Vaccine Approval

AstraZeneca May Skip EUA Process and Seek Full Vaccine Approval

May 11, 2021

AstraZeneca (AZ) may forgo seeking Emergency Use Authorization (EUA) from the FDA and instead go for full approval for its COVID-19 vaccine off the bat.

In March, AZ said that it was gearing up to file for FDA emergency authorization “in the coming weeks,” but April has come and gone without a submission. While an EUA filing is not yet off the table, the drugmaker is reportedly now leaning toward filing a Biologics License Application (BLA).

AZ’s two-dose adenovirus-based vaccine was once seen as a contender to receive the FDA’s first authorization for a coronavirus vaccine and to become a key weapon in the U.S. pandemic response. But a number of setbacks have delayed progress in gathering the two-month follow-up data needed to file for emergency clearance, including a lengthy clinical hold over safety concerns (DID, Oct. 26, 2020).

Because of the delays, the company has yet to file an application for an EUA. But the U.S. has stockpiled millions of doses of the vaccine, and the Biden administration has begun sharing them with other countries as the AZ vaccine is not yet authorized for U.S. distribution (DID, April 27).

The British-Swedish company’s vaccine has been authorized elsewhere, including in the EU and the UK, where it has seen heavy use.

The company did not immediately respond to a request for comment on a potential filing for a full approval.

Partners Pfizer and BioNTech on Friday became the first to file an application with the FDA for full approval after accruing the six months of follow-up data required, and Moderna expects to soon follow suit for its vaccine (DID, May 10). Vaccines that are fully approved by the FDA may be marketed directly to consumers. A full agency approval may also help persuade some vaccine-hesitant Americans to get vaccinated, as the approvals are based on longer-term data.

With the outstanding success of the Pfizer/BioNTech and Moderna vaccines, the White House has said it’s not sure how much use the AZ vaccine will see upon an eventual clearance, whether that comes in the form of an EUA or BLA.

Novavax is also experiencing delays in filing for an EUA and will not make its submission until June at the earliest. Reportedly, the company does not expect to have results from its U.S. phase 3 trial until the end of this month.

In other vaccine news, the World Health Organization (WHO) approved the first nonWestern shot for use under COVAX, a program that helps low- and middle-income nations gain access to vaccines, granting an emergency-use listing for a vaccine from China’s Sinopharm. The Beijing-based, state-owned company aims to expand its production capacity to 3 billion doses annually. — James Miessler

COVID-19

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 02Nov

      How UDI and UDI Data Can — and Must — Be Used for More Than Just Device Identification

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Expert Says FDA Under No Obligation to Educate Companies on Inspection Rights

    • FDA Deems Hamilton Ventilator Recall Class I for Software Issue Causing Device to Stop

    • Survey Shows Nearly All Pharm Techs Face Drug Shortages, Pfizer Plant Shortages Continue Until 2024

    • FDA Shares Premarket Requirements for Device Cybersecurity in Final Guidance

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing